आता परतीच्या पावसावरच भिस्त?

मध्य महाराष्ट्र, मराठवाडा, विदर्भाला प्रतीक्षाच

प्रतिनिधी, पुणे

कोकणात समाधानकारक पाऊस

राज्यात मोसमी पावसासाठी पोषक मुंबई: मुंबई व कोकण पट्ट्यात चांगला पाऊस आणि घरणे भरली असली तरी राज्यात अन्यत्र तेवढा समाधानकारक पाउटर नार्टर राज्यात मासमी पावसासाठी पोषक स्थिती वत्रार होत नसल्याने मागील तीन आठवड्यांपासून राज्याच्या अनेक भागांत जोरदार पावसाऐवजी तुरळक सरीवरच समाधान मानावे लागत आहे. मध्य महाराष्ट्र, मराठवाडा आणि विदर्भात पावसाची ओह कायम आहे. मुंबई है वह व कारणे पश्चात वागला पाऊस आण घरण मंदला असली तरी राज्यात अन्यत्र तेवदा समाधानकारक पाऊस झालेला नाही. मरादवाडा व खान्देशात सरासरीपेका कमी पाऊस झाला आहे. राज्यातील जलाश्चांमध्ये आतापर्यंत ५० टक्के साठा झाला आहे. राज्यात आतापर्यंत कोकणात पावसाने सरासरी पार केली आहे. अन्य पाच विभागांमध्ये सरासरीपेक्षा कमी पाऊस झाला आहे. कोकण (१९० दक्के), मराठवाडा (७० टक्के), नाशिक (६८ टक्के), पुणे (८७ टक्के नागपूर (८३ टक्के) तर अमरावतीमध्ये ८४ टक्के पाऊस झाला आहे. त्यामळे या भागाला आता परतीच्या त्यांकुळ या भागाला आता पत्ताच्या गावसावत अतर्ककृत साहावे लगाणार असत्त्याचे चित्र अस्तून, त्यादृष्टीने हवामान विभागाक हुन अंद्यज व्यक्त करण्यात येत आहेत. राज्यामध्ये जून महिन्नामध्ये दुसऱ्या आणि तिसऱ्या आठवङ्यामध्ये पावसाचा खंड पडला होता. त्यानंतर राज्यातील जलाशयांमध्ये ५२ टक्के साठा झाला असला तरी कोकण आणि पुणे वगळता अन्यत्र साठा क्षमतेच्या तुलनेत ५० टक्क्यांपेक्षा कमीच आहे.

समुद्रातील कमी दाबाचे क्षेत्र नाहीसे झाल्यानंतर जुलैच्या तिसऱ्या आठवड्यापासून राज्याच्या अनेक भागांत पावसाने हजेरी लावलेली नाही. चांगल्या पावसाला सुरुवात झाली होती. काही ठिकाणी जोरदार ते मुसळधार पावसाची नोंदही झाली. त्यानंतर जुलैपासून पुन्हा पावसाने दडी मागील वर्षीही जुलै आणि ऑगस्ट या महिन्यांमध्ये सुमारे सहा आठवडे पावसाने ओढ दिली होती. सद्यःस्थितीत दक्षिण मध्य

्न. बंगालचा उपसागर आणि अरबी

भारतामध्ये मोसमी पाऊस सक्रिय होण्यासाठी अनुकूल स्थिती नसल्याने पावसाची ओढ कायम आहे. मात्र, पावसाचा आढ कायम आह. मात्र, पुढील आठवडाभर कोकण, मध्य महाराष्ट्र आणि विदर्भात काही ठिकाणी, तर मराठवाड्यात तुरळक ठिकाणी हलक्या सरी कोसळण्याचा अंदान आहे.

दहावीच्या प्रश्नपत्रिकेच्या स्वरूपावर नियामकांकडन आक्षेप

दहाञाच्या नव्या अभ्यासक्रमाबरोबरच प्रश्नपत्रिकेच्या स्वरूपातही यंदा बदल झाले असून अभ्यासम्डळाने तयार केलेल्या या प्रश्नपत्रिकेच्या स्वरूपावर विषय तज्ज्ञांनी मात्र आक्षेप घेतले आहेत. दहावीची पाठ्यपुस्तके यंदापासून

बदलली आहेत. त्याचबरोबर प्रश्नपत्रिकांचे स्वरूपही बदलण्यात प्रश्नभागिकाचे स्वरूपक्षी बदलपयात आले आहे. दहाबीच्या प्रश्नपत्रिका राज्यमंडळाकडून नेमण्यात येणाऱ्या विषय तज्ज्ञ समितीकडून तयार करण्यात येतात. यंदा नव्या पाठ्यपुस्तकांबरोबरच या रचनेतही शिक्षण विभागाने बदल केले आहेत. त्यानुसार आता प्रश्नपत्रिका या

त्यानुसार आता प्रश्नपत्रिका या बालभारतीच्या अभ्यासमंडळांकडूनच तयार करण्यात येणार आहेत. नव्या पुस्तकांमध्ये प्रश्नांचे स्वरूप, प्रात्यक्षिके अशा बाबी देण्यात आल्या आहेत. पाठ्यपुस्तकांच्या संचाबरोबरच प्रश्नपत्रिकांचे स्वरूप, संचीवराबरच प्रश्नामुत्रकाच स्वरूप, मूल्यांकनातील बदल, नम्ना प्रश्नापत्रका यांची माहिती असणारे पुस्तकही बालभारतीने तथार केले आहे. मात्र अभ्यास मंडळाने तथार केलेल्या प्रश्नपत्रिका आणि तक्रारी आलेल्या नाहीत. शिक्षकांना शिकवण्यात काही प्रश्नपत्रिकेच्या स्वरूपाबाबत का शंका असतील तर त्यावर मार्ग काढण्यात येईल. गरज असल्यास शिक्षकांना याबाबत

-डॉ. सुनील मगर, संचालक

पाठ्यपुस्तकांमध्ये त्रुटी असल्याची तक्रार राज्यमंडळाच्या विषय समितीने

करता आह.
पाठ्यपूरतकांत दिलेल्या
प्रश्नपत्रिकंत दिलेल्या
प्रश्नपत्रिकंत्या नव्या स्वरूपाप्रमाणे
म्हणजेच 'कृतिपत्रिकं नुसार
विवाध्योता मार्गदर्शन केले जात नाही.
त्यामुळे कृतिपत्रिकंत्या मूळ हेत्त्व
साध्य होत नाही. त्यामुळे अह्यापही
विवाधीं बाजारांत मिळणाऱ्या ावधाया बाजारात मिळणाऱ्या मार्गदर्शक पुस्तकांवरच अवलंज्या आहेत. पुस्तकांतील क्यू आर कोडवरोवर अद्यापही लिंक्स जोडपयात आलेल्या नाहीत, असे आक्षेप नियामक मंडळाने घेतले आहेत.

नागपुरात कोट्यवधींचा कर्जघोटाळा

शेतकऱ्यांच्या नावाने परस्पर उचल

राजेश्वर ठाकरे, नागपूर फसवणूक झालेल्या शेतकऱ्यांची यादी

नागपुरातील नरखेड वालुक्यात ४३ शेतकऱ्यांच्या नावाने प्रत्येकी ४५ ते ५६ लाखांचे कर्ज परस्पर उचलण्यात आल्याचा धकादायक प्रकार उघडकीस आला आहे. भूमिहान शेतमजूमगंच्या नावानेही सीताबाई डोपरे भूमिहीन मघुकर गायकवाड भूमिहीन प्रकाश डंगारे श्यामराव लोणे रामेश्वर गुलाले संखूबाई गाखरे कर्ज उचलण्यात आले असून, या कोट्यवधींच्या घोटाळ्याने नागपुरात कोट्यवधींच्या घोटाळ्याने नागपुरात खळबळ उडाली आहे. कॉर्पोरेशन बँक या राष्ट्रीयीकृत बँकेशी संबंधित हे प्रकरण आहे. यासंदर्भात जलालखेडा पोलीस ठाण्यात तक्रार नोंदवण्यात आली प्रल्हाद मंगल (८) मुनी महाजन (८) विङ्ठल खेपरे (१०) पुरुषोत्तम पंचभाई (१०) पुरुषोत्तम पंचभाई (१०) सीद्धाराम खेपरे

आहे. या शेतकऱ्यांना कॉपेरिशन बँकेच्या विकलाकड्न नोटीसाही बकच्या वाकलाकडून नाद्यसाड आल्या आहेत. सात-बारा आणि इतर बाबींची पडताळणी केल्यारिश्वार शेतकऱ्यांना एक-दोन लाखांचे पीककजंही दिले जात नाही. अनेकदा बँकांचे उंबरटे झजबावे लागतात. मात्र, या प्रकरणात शेतकऱ्यांच्या धोतरे याने परिसरातील शेकडो धातर यान पासस्यताल शकडा शेतक-यांकडून जॉब कार्डसार आधार कार्ड आणि इतर कागदपत्रे घेतली होती. याच कागदपत्रांच्या आधारावर कर्जाची उचल करण्यात आल्याचे समजते. प्रकाश डंगारे यांच्याकडे सहा

नावाने परस्पर ४६ ते ५० लाख कर्ज कसलीही चौकशी न करता दिले गेले आहे. यामुळे बँक अधिकाऱ्यांच्या संगनमताने हा महाघोटाळा झाला असण्याची शक्यता आहे. 'नरेगा'चा रोजगार सेवक असणाऱ्या नीलेश

वर्जवसुलीची कारादेशीर प्रक्रिया सुरू आहे त्यानुसार कर्नदाः आणि हमी घेणारा रांना नोटीस पाठवण्यात आली आहे. यात नेमके काय झाले, हे चौकशीगंतरच पढे चेईल. - गौरी पाटणकर

व्यवस्थापक कॉर्पोरेशन बँक मख्य शास्त्रा नागपुर

प्रकार डगार वा प्याक्षकह सहा एकर रोती आहे. त्यांनी कर्जाची मागणी केली नव्हती, परंतु, त्यांना आठ दिवसांपूर्वी कॉर्पोरान बैंकेची नोटीस आली. त्यात ४५ लाख रुप्यांचे कर्ज २०१७ ला घेण्यात आले असून, व्याजासह ५२ लाख

१६ हजार २८ रुपये भरावे. असे १६ हजार २८ रुपय भराव, अस नमूद करण्यात आले. त्यांच्या कर्जाची हमी कोराडी येथील वेलकमनगरातील नूतनसिंग यांनी घेतल्याचे नमूद आहे. ही नोटीस मिळाल्यानंतर हा

हा नाटास ामळाल्यानतर हा घोटाळा उघडकीस आला, असे प्रकाश डंगारे यांनी 'लोकसत्ता'शी बोलताना सांगितले. एवढ्या मोठ्या प्रमाणात शेतकऱ्यांच्या नावाने कर्ज काढून त्यांची फसवणूक झाल्याची गेल्या काही वर्षांतील पहिली घटना

शाळेच्या इमारतीवरून उडी मारून उपमख्याध्यापकाची आत्महत्या

प्रतिनिधी, मुंबई

अंधेरी येथील सी. डी. बर्फीवाला शाळेचे उपमुख्याध्यापक राम कांबळे (४७) यांनी शाळेच्या इमारतीवरून उडी मारून काबळ (४७) याना शाळच्या इमारतीवरून उडी मारून आत्महत्या केली असून कौटुंबिक प्रश्नांतून ही आत्महत्या केल्याचे समोर येत आहे. 'नैग्रश्यामुळे आत्महत्या कत्त्र असून त्यासाळी कुणालाही जबाबदार धरण्यात येऊ नये असे कांबळे यांनी चिट्ठीत

लिहित आहे.
मालाड येथील रहिवासी
असलेंग्ने कांबळे हे सी. डी.
बफींवाला शाळेत गेली २० वर्षे
विज्ञान आणि गणित विषयाचे
अध्यापन करत होते. विद्यार्थीप्रिय
शिक्षक अशी त्यांची ओळख होती. नेहमीप्रमाणे शुक्रवारी सकाळी ७ वाजता ते शाळेत आले. त्यानंतर साधारण ८ वाजून ४० मिनिटांनी त्यांनी तिसऱ्या

मजल्यावरून खाली उडी मारली. अवाज ऐकू न शाळेतील शिक्षक आणि कर्मचाऱ्यांनी इमारतीच्या मागील बाजुस धाव घेतली. त्यांनेत कांबळे यांना उपचारांसाठी जबळील रुग्णालयात नेपपात आले. मात्र लायुपीत त्यांचा मुख् झाला होता, अशी माहिती शाळेतील कर्मचाऱ्यांनी दिली. कांबळे यांच्या मागे पत्ली आणि मुलगा असा परिवार आहे. या घटनेम्मठ गाळेता सडी

या घटनेमुळे शाळेला सुट्टी जाहीरकरून तातडीने विद्यार्थ्यांना जाहार करून तात खना विद्याच्याना घरी पाठवण्यात आले. आठवडा अखेर असल्यामुळे पुढील दोन दिवस शाळा बंद राहणार असून सोमवारनंत विद्याच्यास्त्रीत समुपदेशन सार्वे आयोजन करण्यात येणार आहे.

या प्रकरणी डी. एन. या प्रकरणा छ। एन, नगर पोलिसांनी अपघाती मृत्यूची नोंद घेत पुढील चौकशी व तपास सुरू केला आहे.

चुकीचे औषध देणाऱ्या औषध विक्रेत्याचा परवाना रह

प्रतिनिधी, मुंबई

औषध ब्रॅण्डच्या नावातील सारखेपणामुळे संग्रम निर्माण होऊन फॉलिक ॲसिडच्या औषधोऐवजी कर्करोगाचे औषध दिल्याने रुग्णाचा मृत्यू झाल्याप्रकरणी औषधविक्रेत्याचा ञ्चाल्याप्रकरणा आषधावक्रत्याचा परवाना कायमस्वरूपी रद्द करण्यात आला आहे. फार्मासिस्टच्या गैरहजेरीत औषधांची विक्री करणाऱ्या विक्रेत्यांना चाप लावण्यासाठी राज्य सरकारकडून कठोर कारवाई करण्यात आली आहे. भविष्यात करण्यात आला आह. माक्य्यात अशा घटना घट्ट नये यासाटी ब्रॅण्ड नावाप्रमाणे औषधांना मंजुरी देण्याची मागणी राज्य अन्न व औषध प्रशासन मंत्री गिरीश बापट यांनी केंद्र सरकारकडे केली आहे. औषधांच्या ब्रॅण्डच्या नावातील

औषधांच्या ब्रॅगडच्या नावातील सारखेपणा रुणाच्या निवाबर बेतत्याचे वृत्त 'लोकसत्ताने' 'औषधांतील नामसाध्ययाने मृत्यू ब्राल्यास जवाबदारी कुणाची? 'या मध्यव्याखाली हुँ रे गाँची प्रसिद्ध केले होते. त्यानंतर या घटनेची गंभीर दखल घेत राज्य अन्न व औषध प्रशासन मंत्री शिरीश व्याप्ट यांनी गिरीश बापट यांनी यांच्याकडे तक्रार करून यावर औषधविक्रेत्याचा परवाना विक्रेत्याने स्थगिती आणली होती.

देण्यात येत होती परिपत्रकानुसार ही

काराम्बरक्षी रह केला आहे कायमस्वरूपा रद्द कला आह. मालाड येथे राहणारे दिगंबर धुरी यांच्या पायाला जखम झाल्याने ५ ऑक्टोबर रोजी त्यांना नर्सिंग होममध्ये उपचारासाठी नेण्यात होममध्ये उपचारासाठी नेपणात आठ होते. वेंक्टरांनी लिड्न वेंक्टरांनी लिड्न करपेश व्यास याच्या करपेश मेडिकल टरोसमध्य प्रेतले. त्यांतर जवळपास आठ दिवसानी तोंड सुजणे, पशी कमी होणे अशा तक्रारी दिलंबर चंत्रां सुरू शाल्या. त्यांची पृकृती चिंताजनक झाल्यानंतर रुणाळ्यात वाखळ केंठ उपजायत्यस्थान व्यांक उपचारादरम्यान त्यांना विक्रेत्याने डॉक्टरांनी औषधविकेत्याने औषधिवक्रत्यानं डांक्टरानां लिहिलेल्या अशक्तपणा कमी करण्याच्या फॉलिमॅक्स या औषधाऐवजी याच नावासारखे असणारे परंतु कर्करोगासाठी दिले जाणारे फॉलिट्रॅक्स हे औषध दिल्याचे समोर आले. उपचार सुरू असतानाच १५ ऑक्टोबर रोजी असतानाच १५ आकटाबर राजा धुरी यांचे निधन झाले. तक्रारीनंतर अन्न व औषध प्रशासनाने या प्रकरणाची चौकशी करून विक्रेत्याचा परवाना १ मे पासून रह करण्यात आरु होता. मात्र अन्न व औषध मंत्री गिरोश बापट

resums in accordance with the recognition and measurement principles as per trie in Fish the format as per trie. Effective 1 April, 2018, the Company adopted IND AS 115 or IFRS 15" Revenue from Contracts with custon material effect on the financial results on adoption of IND AS 115 or IFRS 15, as the case may be. The list of subsidiaries as of 30 June, 2018 is provided in Annexure A.

The figures for the quarter ended 31 March 2018 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the figures for the third quarter of the relevant financial year.

11. Previous period's figures have been re-grouped/re-classified wherever necessary.

List of entities included in the consolidated financial results for the quarter ended 30 June 2018

AliGenmark Pharmaceuticals (Europe) RSD Lid., U.K. Z.Glenmark Pharmaceuticals Europe Ltd., U.K. 3.Glenmark Pharmaceuticals S.R.O. 4.Glenmark Pha helimital Gmb 31.Glenmark Pharmaceuticals Canada Inc. (formerly Glenmark Generics Canada Inc.) 32.Glenmark Pharmaceuticals Kerya Ltd 33.Glenmark Ltd 33.Glenmark Pharmaceuticals Kerya Ltd 33.Glenmark Pharmaceuticals Nordic AB 38.Glenmark Ukraine LtC Glenmark-Pharmaceuticals Nordic AB 38.Glenmark Ukraine LtC Glenmark-Pharmaceuticals Ecuador S.A. 40.Glenmark Pharmaceuticals Singapore Pte. Ltd.

For and on behalf of the Board of Glenn Saldanha Chairman & Managing Directo

Mumbai, August 10, 2018

िक्यता Sat, 11 August 2018 कोक्यता epaper.loksatta.com/c/31227459

मान्यता दण सुरू केळे. त्यामुळे ब्रॅण्डनावावर कोणताही वचक राहिलेला नाही. नाट सारखेपणामुळे भविष्यात अशा घटना घडू नये यासाठी पूर्वीप्रमाणे

ब्रॅण्डनावानुसार मंजुरी देण्याची पद्धत सुरू करावी, अशो मागणी गिरीश बापट यांनी केंद्र शासनाकडे केली आहे.

औषधांच्या ब्रॅण्डनावानसार मान्यता मागणी

म्यनि मृत्यु झार -

यासंबंधीचे वृत 'लोकसत्ता' ने २५ जुलै रोजी प्रसिद्ध केले होते.









glenmark PHARMACEUTICALS LTD.

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026. rporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Andheri (East), Mumbai 400 099.

Tel: 91 22 4018 9999 Fax: 91 22 4018 9986 Email: complianceofficer@glenmarkpharma.com Website: www.glenmarkpharma.com CIN: L24299MH1977PLC019982

Statement of Unaudited Financial Results for the quarter ended 30th June. 2018

	(Refer notes below) ended 30-06-20	Standalone (Ind AS)			Consolidated (Ind AS)			Consolidated (IFRS)					
Sr. No.		Quarter ended 30-06-2018 (Unaudited)	Quarter ended 31-03-2018 (Audited) (Refer note 10	Quarter ended 30-06-2017 (Unaudited)	Year ended 31-03-2018 (Audited)	Quarter ended 30-06-2018 (Unaudited)	Quarter ended 31-03-2018 (Audited) (Refer note 10)	Quarter ended 30-06-2017 (Unaudited)	Year ended 31-03-2018 (Audited)	Quarter ended 30-06-2018 (Unaudited)	Quarter ended 31-03-2018 (Audited) (Refer note 10)	Quarter ended 30-06-2017 (Unaudited)	Year ended 31-03-201 (Audited)
1	Revenue from operations									03 200 00			
	(a) Net sales	15,632.28	15,063.27		60,960.52	21,293.66			89,722.32	21,293.66	22,478.93	23,293.94	89,722.3
	(b) Other operating income	551.79	1,614.18	368.52	3,358.32	362.51	319.23	336.08	1,308.38	362.51	319.23	336.08	1,308.3
- 2	Total Revenue from operations	16,184.07	16,677.45		64,318.84	21,656.17		23,630.02	91,030.70	21,656.17	22,798.16	23,630.02	
11	Other income	1,736.49	442.98	425.88	1,804.22	1,382.16	695.52	152.87	914.00	1,382.16	695.52	152.87	914.0
Ш	Total income (I + II)	17,920.56	17,120.43	15,903.66	66,123.06	23,038.33	23,493.68	23,782.89	91,944.70	23,038.33	23,493.68	23,782.89	91,944.7
IV	Expenses	2000000000	20000000000		100701070000		30 Sept. 200			120000000000	0.0000000000000000000000000000000000000		
	(a) Cost of materials consumed	5,147.65	5,312.54	5,000.21	20,385.67	4,951.83		4,856.67	21,501.10	4,951.83	6,149.42	4,856.67	21,501.1
	(b) Purchase of stock-in-trade	746.72	632.69	693.06	2,881.77	2,452.52	1,734.00	2,609.16	7,547.45	2,452.52	1,734.00	2,609.16	7,547.4
	(c) Changes in inventories of finished goods,	10000000	100000	900.27532	12.22.22	10000000	2777		USSESS.	200 100	155.000	100000000000000000000000000000000000000	15-225-11
	work-in-progress and stock-in-trade	(172.13)	347.33	(109.34)	518.47	183.62	(40.39)	(251.37)	1,337.12	183.62	(40.39)	(251.37)	1,337.
	(d) Employee benefits expense	2,296.89	2,323.30	2,077.68	10,219.21	4,525.09			18,718.41	4,525.09	4,642.73	3,843.96	
	(e) Finance costs	551.71	507.22	457.37	1,908.98	790.12	743.88	708.61	2,855.67	790.12	743.88	708.61	2,855.6
	(f) Depreciation and Amortisation expense	334.17	298.18	299.41	1,182.04	793.84	735.32	777.32	3,018.76	944.78	894.24	877.21	3,540.6
	(g) Other expenses	4,061.97	4,758.48	4,286.75	16,838.67	6,074.28		6,797.11	25,772.89	6,074.28	7,046.35	6,797.82	
	Total expenses (IV)	12,966.98	14,179.74	12,705.14	53,934.81	19,771.30		19,341.46	80,751.40	19,922.24	21,170.23	19,442.06	81,276.7
٧	Profit/(loss) before exceptional items and tax (III-IV)	4,953.58	2,940.69	3,198.52	12,188.25	3,267.03	2,484.67	4,441.43	11,193.30	3,116.09	2,323.45	4,340.83	10,667.9
VI	Exceptional items	-	-	-	-	-	-	-				-	
VII	Profit/(loss) before tax (V-VI)	4,953.58	2,940.69	3,198.52	12,188.25	3,267.03	2,484.67	4,441.43	11,193.30	3,116.09	2,323.45	4,340.83	10,667.9
/III	Tax expense :												
	Current tax	1,070.08	733.52	682.31	2,706.77	1,116.28	961.43	790.13	3,256.90	1,116.28	948.64	790.13	3,244.1
	Deferred tax	(90.41)	(7.95)	(192.17)	(661.99)	(179.15)	6.97	317.49	(102.30)	(227.98)	(135.56)	295.93	(318.9
IX	Profit/(loss) for the period (VII - VIII)	3,973.91	2,215.12	2,708.38	10,143.47	2,329.90	1,516.27	3,333.81	8,038.70	2,227.79	1,510.37	3,254.77	7,742.8
X	Other comprehensive income							-					
	A (i) Items that will not be reclassified to profit or loss (ii)Income tax relating to items that will not be	25.10	36.41	(8.60)	(10.20)	28.10	9.93	(15.46)	41.96	28.10	9.93	(15.46)	41.9
	reclassified to profit or loss	(8.77)	(12.60)	2.98	3.53	(9.16)	(9.15)	3.98	(3.25)	(9.16)	(9.15)	3.98	(3.2
	B (i) Items that will be reclassified to profit or loss (ii)Income tax relating to items that will be reclassified to profit or loss					(2,725.02)	(511.28)	(354.51)	(778.78)	(2,753.50)	(463.92)	(350.19)	(696.1
XI	Total comprehensive income	3.990.24	2,238.93	2,702.76	10,136.80	(376.18)	1.005.77	2.967.82	7,298.63	(506.77)	1,047.23	2.893.10	7.085.3
	Total comprehensive income attributable to:									1			
	- Non-controlling interests					(0.04)	0.47	0.13	0.92	(0.04)	0.47	0.13	0.5
	- Owners of the Company	3.990.24	2.238.93	2,702.76	10,136,80	(376.14)	1.005.30		7.297.71	(506.73)	1.046.76	2.892.97	7.084.4
III	Other equity	250000	10/ 20/20		1.03.632.24			-	51,352.60	,	100		55,608.3
	Earning Per Share (EPS)												
	(of Re. 1/- each) (not annualised)												
	Basic Earnings Per Share (in Rupees)	14.08	7.85	9.60	35.95	8.26	5.37	11.81	28.49	7.90	5.35	11.53	27.4
	Diluted Earnings Per Share (in Rupees)	14.08	7.85	9.60	35.95	8.26	5.37	11.81	28.49	7.90	5.35	11.53	27.4

sults were reviewed by the Audit Committee at its meeting held on 9 August, 2018 and approved at the meeting of the Board of Directors held on 10 August, 2018

The results for the quarter ended 30 June, 2018 presented were subjected to a "Limited Review" by statutory auditors of the Company who have issued an unmodified report on the said results. The Financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunde and in terms of Regulation 30 of the SEBI (Listing and Disclosure Requirements). Regulations, 2015 and SEBI circular dated 5 July, 2016. The Company has voluntarily presented the consolidate results in accordance with the recognition and measurement principles as per the IFRS in the format as per the Regulation 33(1)(c) of the SEBI (Listing and Disclosure Requirements) Regulations, 2015. mers", as the case may be using the modified restrospective transition method. There we

The Company operates in one reportable business segment i.e., Pharmaceuticals

The Company operates in one reportation business segment i.e., Prantancouticals.

As at 30 June, 2018, pursuant to Employee Slock Options Scheme 2016, 5.56.91 d options were outstanding, which upon exercise are convertible into equivalent number of equity sha Diluted EPS has been computed considering the effect of conversion of ESOPs.

Post implementation of Goods and Service Tax ("GST") with effect from 1 July, 2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier period duty which is now subsumed in GST. Revenue from operations for year ended 31 March, 2018 includes excise duty upto 30 June, 2017. Accordingly, revenue from operations for query, 2018 in not comparable with previous periods presented.

Annexure A

liet of antities included in the consolidated financial results for the quarter ended 30 June 2018

FINANCIAL EXPRESS

30.06.2017

(Unaudited)

482.21

(136.96)

(136.96)

(136.96)

(137.01)

2,952.93

(0.46)*

(0.46)*

On behalf of the Board of Directors

For RattanIndia Power Limited

Jayant Kawale

Consolidated (IFRS)

Managing Director

Quarter Ended

31.03.2018

(Audited)

654.92

2.93

2.93

(3.98)

(3.95)

2,952.93

 $(0.01)^*$

 $(0.01)^*$

30.06.2018

(Unaudited)

690.72

(7.60)

(7.60)

(7.60)

(7.54)

2,952.93

(0.03)*

 $(0.03)^*$

RattanIndia Power Limited

(Formerly known as Indiabulls Power Limited.) Extract from the Unaudited Financial Results of RattanIndia Power Limited

(Formerly Known as Indiabulls Power Limited.) for the Quarter ended 30 June 2018

The above is an extract of the detailed format of Financial Results of the quarter ended 30 June 2018 filed with the stock exchanges under Regulation 33 of the SEBI (Listing and other Disclosure requirements) Regulations, 2015. The full format of the unaudited financial results are available on the Company's website at

(i) The Company has a non-current investment of Rs. 3,026.26 crore in, inter corporate deposits (classified under current assets) of Rs. 48.48 crore and trade

receivable of Rs. 5.33 crore recoverable from RattanIndia Nasik Power Limited, a wholly-owned subsidiary of the Company, as at 30 June 2018. The

subsidiary company has incurred losses since its inception and is yet to commence operations. The accumulated losses in the subsidiary company amount to

Rs. 1,965.43 crore as at 31 March 2018, and the management of the subsidiary company had determined that a material uncertainty exists, as at 31 March

2018, that may cast significant doubt about the subsidiary company's ability to continue as a going concern. However, in the absence of any impairment

assessment performed by the management, we are unable to obtain sufficient appropriate evidence to comment on any adjustment that may be required to be

made to the carrying values of the above mentioned non-current investment, inter corporate deposits and trade receivables as at 30 June 2018, and the

Rs. 122.58 crore recoverable from Bracond Limited, a wholly-owned subsidiary of the Company, as at 30 June 2018. In the absence of any impairment

assessment performed by the management, we are unable to obtain sufficient appropriate evidence to comment on any adjustment that may be required to be

made to the carrying values of the above mentioned non-current investment and inter corporate deposits as at 31 March 2018, and the consequential impact

(ii) The Company has a non-current investment of Rs. 432.77 crore in and inter corporate deposits (classified as loans under non-current assets) of

(b) The Auditors in their Limited Review Report on the standalone financial statement for the quarter ended 30 June 2018 have brought out that:

Consolidated (Ind AS)

(Rs. In Crore)

Year Ended

31.03.2018

(Audited)

2,015.38

(411.47)

(411.47)

(418.38)

(418.14)

2,952.93

1,654.44

(1.42)

(1.42)

PURAVANKARA®

PURAVANKARA LIMITED

Registered Office: No.130/1, Ulsoor Road, Bengaluru-560 042, India Corporate Identification Number: L45200KA1986PLC051571 Email: investors@puravankara.com Tel: +91-80-43439999 | Fax: +91-80-2559 9350

Extract of standalone and consolidated unaudited financial results for the quarter ended 30 June 2018

ulars	Quarter ended	Preceding Quarter	Corresponding	Previous	O. order			
	30.06.2018 [Unaudited]	ended 31-03.2018 [Audited]		Year ended 31.03.2018	30.06.2018	Preceding Quarter ended 31-03.2018 [Audited]	Corresponding Quarter ended 30.06.2017 [Unaudited]	Previous Year ended 31.03.2018 [Audited]
come from operations	269.43	175.90	214.66	885.60	382.02	287.95	338.49	1,414.90
ofit/(loss) for the period (before Tax, Exceptional and/or Extraordinary items)	26.38	23.46	11.17	86.99	35.47	27.79	31.88	131.23
fit/(loss) for the period before tax (after Exceptional and/or Extraordinary items)	26.38	23.46	11.17	86.99	35.47	27.79	31.88	131.23
ofit/(loss) for the period after tax (after Exceptional and/or Extraordinary items)	21.63	23.46	7.10	77.23	26.85	24.55	20.07	91.40
omprehensive Income for the period (comprising Profit/(Loss) for the period (after tax) and omprehensive income (after tax)	21.22	23.69	7.13	76.76	26.46	24.88	20.05	91.16
Share Capital (face value * 5/share)	118.58	118.58	118.58	118.58	118.58	118.58	118.58	118.58
es (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year		-	-	1,874.10	-	-	-	2,274.59
gs per share (before extraordinary items) (nominal value ₹ 5 per share)								
(7)	0.91	0.99	0.30	3.26	1.13	1.04	0.85	3.85
: (₹)	0.91	0.99	0.30	3.26	1.13	1.04	0.85	3.85
9	s per share (before extraordinary items) (nominal value ₹ 5 per share) ₹)	s per share (before extraordinary items) (nominal value ₹ 5 per share) ₹) 0.91	s per share (before extraordinary items) (nominal value ₹ 5 per share) ₹) 0.91 0.99	s per share (before extraordinary items) (nominal value ₹ 5 per share) ₹) 0.91 0.99 0.30	s per share (before extraordinary items) (nominal value ₹ 5 per share) ₹) 0.91 0.99 0.30 3.26	s per share (before extraordinary items) (nominal value ₹ 5 per share) ₹) 0.91 0.99 0.30 3.26 1.13	s per share (before extraordinary items) (nominal value ₹ 5 per share) ₹) 0.91 0.99 0.30 3.26 1.13 1.04	s per share (before extraordinary items) (nominal value ₹ 5 per share) ₹) 0.91 0.99 0.30 3.26 1.13 1.04 0.85

- 1 The above consolidated financial results of Puravankara Limited (the Company') have been reviewed by the Audit Committee and taken on record at the meeting of the Board of Directors of the Company held on 10.08.2018. The statutory auditors of the Company have carried out a limited review on the above consolidated financial results of the Company
- 2 The Group's business activity falls within a single reportable segment, i.e., real estate development. Hence, there are no additional disclosures to be provided under Ind-AS 108 Segment information with respect to the single reportable segment. Further, the Group is domiciled in India and does not have significant foreign operations. Ind AS 115 Revenue from Contracts with Customers and amendments to Ind AS 40 Investment Property consequent to issuance of Ind AS 115, mandatory for reporting periods beginning on or after April 1, 2018,
- from real estate projects and gain/loss arising from derecognition of investment property. The Group has applied the modified retrospective approach to all contracts as of April 1, 2018 and has given impact of application of Ind AS 115 and amendments to Ind AS 40 by debit to retained earnings as at the said date by Rs. 610 crores (net of tax). Accordingly, the comparatives have not been restated and hence not comparable with previous period figures. Due to the application of Ind AS 115 and amendments to Ind. AS 40 for the quarter ended June 30, 2018, revenue from operations is higher by Rs. 191 crores (including gain on sale of investment property of Rs. 27 crores) and net profit after tax (before non controlling

replaces existing requirements of recognition of revenue and derecognition of investment property. The application of Ind AS 115 and Amendments to Ind AS 40 have impacted the Group's accounting for revenue

- interests) is higher by Rs.78 crores. The basic and diluted EPS for the period is Rs.1.13 per share, instead of loss per share of Rs. 2.18 per share. 4 The Board of Directors of the Company at their meeting held on August 10, 2018 have recommended a final dividend of Rs. 1.60 per equity share of Rs. 5 each for the financial year ended March 31, 2018. The said
- proposed dividend are subject to approval at the ensuing annual general meeting and are not recognised as a liability (including dividend distribution tax thereon) as at 30.06.2018. The above is an extract of the detailed format of quarter ended financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The

DATED: 06.08.2018

Estimated cost

(As per Min qty.)

2.99 crore

Opening date of part-I

03.09.2018 at 15.00 Hrs

UHBVN, Panchkula

Superintending Engineer/P-II (MM)

full format of the quarter ended financial results are available on the website of Stock Exchanges at 'www.bseindia.com' and 'www.nseindia.com' and on the company's website at 'www.puravankara.com' For and on behalf of the Board of Directors of

Puravankara Limited

(E/Crores, except share and per share data)

Nani R Choksey Joint Managing Director

DIN 00504555

Bengaluru 10 August 2018

> UTTAR HARYANA BIJLI VITRAN NIGAM Office of The Chief Engineer/MM, Shakti Bhawan,

Regd. & Corp. Offices C-16 Vidyut Sadan Sector 6, Panchkula Haryana Ph. No. 0172-3019133 Fax: 0172-3019119

> Web Site: www.uhbvn.com CIN No. U40109HR1999SGC034166 E-mail: cgmmmuhbvn@gmail.com **NOTICE INVITING TENDERS** (only through e-procurement)

NOTICE INVITED TENDER No. 221/UH/MM/XEN/P-IV/MM/QH-II/1982

Offers are invited for procurement of following material on FIRM Price &

'FOR' destination basis anywhere in Haryana by fixing the annual rate

Last date of submission

Tender documents having detailed terms and conditions can be

seen/downloaded from the portal https:// haryanaeprocurement.gov.in

NOTICE INVITING

E-TENDER

e-Tender No. 11 of 2018-

2019 of EE/BD/PHED, vide

Memo bearing No. 1382/BD

Dated 10.08.2018

e-Tender is hereby invited

on behalf of the Governor of

West Bengal, vide e-Tender

NIET_11 of 2018-2019

2018_PHED_185959_1 to

4) in Connection with

"Sinking of Ground Bored

Tube Well in different

Block, under Dakshin

Dinapur District" for details

https://etender.wb.nic.in.

Online Bid Submission Start

and end date 11.08.2018 at

10.00 A.M. and 27.08.2018

upto 02.00 P.M. respectively.

Sd/-

Executive Engineer

Balurghat Division, PHED

please see website

WBPHED/EE/BD/

ID

Max=78000 DHBVN Min.=140000 Max=210000

Min.= 192000

Max= 288000

TOTAL

contract as per details given below:-

11 KV 5 KN Polymer Type Pin Insulator (In Nos.) along with Pin as per Nigam Technical UHBVN

09.08.2018 at 10.00 Hrs 03.09.2018 at 13.00 Hrs

and www.uhbvn.org.in/web/portal/tenders

(Tender

Specification no. 84. SE/R-I/P&D/Xen-DD- Min.=52000

Description of item

Date of start

70053/HRY

Sector 6, Panchkula. Tel.: 2561931-39, 2560438 Fax: 0172-2566404

on the accompanying standalone financial results.

Particulars

Basic (Rs.)

Notes:

Diluted (Rs.)

CIN: L40102DL2007PLC169082

Place: New Delhi

Date : 10 August, 2018

Standalone (Ind AS)

Total income from operations

tax and other comprehensive income (net of tax)]

(for continuing and discontinued operations)

*(EPS for the quarter are not annualised)

Net Profit/ (Loss) for the period (before tax, exceptional and/or extraordinary items)

Net Profit/ (Loss) for the period before tax (after exceptional and/or extraordinary items)

Total comprehensive income/(loss) for the period [comprising profit/(loss) for the period after

Other Equity (excluding revaluation reserve) as shown in the balance sheet of previous year

www.rattanindia.com and the Stock Exchange websites at www.bseindia.com and www.nseindia.com.

Net Profit' (Loss) for the period after tax (after exceptional and/or extraordinary items)

Paid-up equity share capital (Face Value of Rs. 10 per Equity Share)

consequential impact on the accompanying standalone financial results.

Registered Office: 5th Floor, Tower-B, Worldmark 1, Aerocity, New Delhi - 110037

Earnings Per Share (Face Value of Rs. 10 per Equity Share)

glenmark PHARMACEUTICALS LTD.

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026.

Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Andheri (East), Mumbai 400 099.

Tel: 91 22 4018 9999 Fax: 91 22 4018 9986 Email: complianceofficer@glenmarkpharma.com Website: www.glenmarkpharma.com

CIN: L24299MH1977PLC019982

Statement of Unaudited Financial Results for the quarter ended 30th June, 2018

Particulars Sr. Quarter Quarter Year Quarter Quarter Quarter Quarter Year Quarter Quarter ended No. (Refer notes below) 30-06-2018 31-03-2018 30-06-2017 31-03-2018 30-06-2018 31-03-2018 30-06-2017 31-03-201 30-06-2018 31-03-2018 30-06-2017 31-03-2018 (Audited) (Unaudited) (Audited) (Unaudited) (Audited) (Unaudited) (Audited) (Unaudited) (Audited) (Unaudited) (Unaudited) (Audited) (Refer note 10) (Refer note 10) (Refer note 10) Revenue from operations (a) Net sales 15,632.28 15,063.27 15,109.26 60,960.52 21,293.66 22,478.93 23,293.94 89,722.32 21,293.66 22,478.93 23,293.94 89,722.32 (b) Other operating income 551.79 1,614.18 368.52 3,358.32 362.51 319.23 336.08 1,308.38 362.51 319.23 336.08 1,308.38 Total Revenue from operations 16,677.45 15,477.78 64,318.84 21,656.17 22,798.16 23,630.02 91,030.70 21,656.17 22,798.16 23,630.02 91,030.70 16,184.07 Other income 442.98 425.88 1,804.22 1,382.16 695.52 152.87 914.00 1,382.16 695.52 152.87 914.00 1,736.49 17,120.43 15,903.66 66,123.06 23,038.33 | 23,493.68 | 23,782.89 | 91,944.70 | 23,038.33 | 23,493.68 | 23,782.89 | 91,944.70 Total income (I+II) 17,920.56 IV Expenses (a) Cost of materials consumed 5,147.65 5,312.54 5,000.21 20,385.67 4,951.83 6,149.42 4,856.67 21,501.10 4,951.83 6,149,42 4,856.67 21,501.10 (b) Purchase of stock-in-trade 746.72 632.69 693.06 2,881.77 2,452.52 1,734.00 2,609.16 7,547.45 2,452.52 1,734.00 2,609.16 7,547.45 (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (172.13)347.33 (109.34)518.47 183.62 (40.39)(251.37)1,337.12 183.62 (40.39)(251.37)1,337.12 (d) Employee benefits expense 2,296.89 2,323.30 2,077.68 10,219,21 4,525.09 4,642.73 3,843.96 18,718.41 4,525.09 4,642.73 3,843.96 18,718.41 551.71 507.22 457.37 1,908.98 790.12 743.88 708.61 2,855.67 790.12 743.88 708.61 2,855.67 (e) Finance costs (f) Depreciation and Amortisation expense 334.17 298.18 299.41 1,182.04 793.84 735.32 777.32 3,018.76 944.78 894.24 877.21 3,540.67 4,758.48 4,286.75 16,838.67 6.074.28 7,044.05 6,797.11 25,772.89 6.074.28 7,046.35 6,797.82 25,776.33 (g) Other expenses 4,061.97 21,009.01 14,179.74 12,705.14 53,934.81 19,771.30 80,751.40 19,922.24 21,170.23 19,442.06 81,276.75 Total expenses (IV) 12,966.98 19,341.46 V Profit/(loss) before exceptional items and tax (III-IV) 2,940.69 3,198.52 12,188.25 3,267.03 2,484.67 4,441.43 11,193.30 3,116.09 2,323.45 4,340.83 10,667.95 4,953.58 VI Exceptional items VII Profit/(loss) before tax (V-VI) 4,953.58 12,188.25 4,441.43 11,193.30 2,323.45 4,340.83 10,667.95 2,940.69 3,198.52 3,267.03 2,484.67 3,116.09 VIII Tax expense : Current tax 733.52 682.31 2,706.77 3,256.90 948.64 790.13 1,070.08 1,116.28 961.43 790.13 1,116.28 3,244.11 Deferred tax (7.95)(192.17)(661.99)(179.15)6.97 317.49 (102.30)(227.98)(135.56)295.93 (318.99)(90.41)2,708.38 IX Profit/(loss) for the period (VII - VIII) 3,973.91 2,215.12 10,143,47 2,329.90 1,516.27 3,333.81 8,038.70 2,227.79 1,510.37 3,254.77 7,742.83 Other comprehensive income A (i) Items that will not be reclassified to profit or loss (15.46)41.96 9.93 41.96 25.10 36.41 (8.60)(10.20)28.10 9.93 28.10 (15.46)(ii)Income tax relating to items that will not be reclassified to profit or loss (12.60)2.98 3.53 (9.15)(3.25)(9.16)(9.15)3.98 (3.25)(8.77)(9.16)3.98 (350.19)B (i) Items that will be reclassified to profit or loss (511.28)(354.51)(778.78) (2,753.50) (463.92)(696.17)(2,725.02)(ii)Income tax relating to items that will be reclassified to profit or loss 7,085.37 2,702.76 10,136.80 1,047.23 XI Total comprehensive income 3,990.24 2,238.93 1,005.77 2,967.82 7,298.63 (506.77)2,893.10 (376.18)XII Total comprehensive income attributable to: Non-controlling interests 0.13 0.47 0.92 (0.04)0.47 0.92 (0.04)0.13 2,702.76 Owners of the Company 2,967.69 7,297.71 2,892.97 7,084.45 3,990.24 2,238.93 10,136.80 (376.14)1,005.30 (506.73)1,046.76 Other equity .03,632.24 51,352.60 55,608.37 Earning Per Share (EPS) (of Re. 1/- each) (not annualised)

J. TAPARIA PROJECTS LIMITED CIN: L74210WB1980PLC032979

Regd. Office: 3, SYNAGOUGE STREET, KOLKATA - 700 001 Telephone: 033 2230 5244, E-mail: info@jtapariaprojects.com, Wetsite: www.itapariaprojects.com STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE

QUARTER ENDED JUNE 30, 2018

QUANTER ENDED JUNE 30, 2016. (Rs. in Lakhs)									
	STANDALONE								
5	Quarter	Quarter	Quarter	Year					
Particulars	ended	ended	ended	ended					
	June 30,	March 31,	June 30,	March 31,					
	2018	2018	2017	2018					
	(Unaudited)	(Audited)	(Unaudited)	(Audited)					
Total income from operations (net)	0.036	1.266	0.180	1.792					
Net Profit / (Loss) from ordinary activities				I					
after tax	-6.244	-1.643	-5.678	-10.383					
Net Profit / (Loss) for the period after tax									
(after Extraordinary items)	-6.240	-1.643	-5.678	-10.383					
Equity Share Capital	1620.000	1620.000	1620.000	1620.000					
Reserves (excluding Revaluation Reserve									
as shown in the Balance Sheet of				I					
Previous year)	0.000	0.000	0.000	172.973					
Earnings Per Share (before extraordinary				I					
items) (of Rs. 10/- each)									
Basic:	-0.039	-0.010	-0.035	-0.064					
Diluted :	-0.039	-0.010	-0.035	-0.064					
Earnings Per Share (after extraordinary									
items) (of Rs. 10/- each)									
Basic:	-0.039	-0.010	-0.035	-0.064					
Diluted :	-0.039	-0.010	-0.035	-0.064					
Note:									

The above is an extract of the detailed format of Financial Results for the Quarter ended 30.06.2018 filed with the Stock Exchange under Regulation 33 of the SEBI

(Listing Obligations and Disclosure Requirements) Regulations, 2015. The full

format of the Financial Results for the Quarter ended 30.06.2018 is available on the Stock Exchange websites. Company's website: http://jtapariaprojects.com/financial-result.php

BSE Limited: www.bseindia.com Notes:

Place : Kolkata

Date: 10th August, 2018.

- 1) The said financial results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors of the Company at their respective meetings held on 10th August 2018.
- 2) In accordance with the requirements under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Statutory Auditors have performed a limited review of the financial results of J. Taparia Projects Limited for the quarter ended 30th June 2018. There are no qualifications in the limited review report issued for the said period.

For and on behalf of the Board of J. Taparia Projects Limited

Sanjit Dhawa DIN: 05162937 **Managing Director**

1. The above results were reviewed by the Audit Committee at its meeting held on 9 August, 2018 and approved at the meeting of the Board of Directors held on 10 August, 2018

7.85

7.85

2. The results for the quarter ended 30 June, 2018 presented were subjected to a "Limited Review" by statutory auditors of the Company who have issued an unmodified report on the said results.

9.60

9.60

The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 5 July, 2016. The Company has voluntarily presented the consolidated results in accordance with the recognition and measurement principles as per the IFRS in the format as per the Regulation 33(1)(c) of the SEBI (Listing and Disclosure Requirements) Regulations, 2015.

35.95

35.95

8.26

8.26

5.37

5.37

11.81

11.81

28.49

28.49

7.90

7.90

5.35

5.35

11.53

11.53

27.44

27.44

- Effective 1 April, 2018, the Company adopted IND AS 115 or IFRS 15 " Revenue from Contracts with customers", as the case may be using the modified restrospective transition method. There was no material effect on the financial results on adoption of IND AS 115 or IFRS 15, as the case may be.
- The list of subsidiaries as of 30 June, 2018 is provided in Annexure A.

Basic Earnings Per Share (in Rupees)

Diluted Earnings Per Share (in Rupees)

- The Company operates in one reportable business segment i.e., Pharmaceuticals.
- As at 30 June, 2018, pursuant to Employee Stock Options Scheme 2016, 5,56,914 options were outstanding, which upon exercise are convertible into equivalent number of equity shares. Diluted EPS has been computed considering the effect of conversion of ESOPs.
- 9. Post implementation of Goods and Service Tax ('GST') with effect from 1 July, 2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier period includes excise duty which is now subsumed in GST. Revenue from operations for year ended 31 March, 2018 includes excise duty upto 30 June, 2017. Accordingly, revenue from operations for guarter ended 30 June. 2018 is not comparable with previous periods presented. 10. The figures for the quarter ended 31 March 2018 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the figures for the
- third quarter of the relevant financial year.

14.08

Previous period's figures have been re-grouped/re-classified wherever necessary.

Annexure A List of entities included in the consolidated financial results for the quarter ended 30 June 2018

1.Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K. 2.Glenmark Pharmaceuticals Europe Ltd., U.K. 3.Glenmark Pharmaceuticals S.R.O. 4.Glenmark Pharmaceuticals SK, S.R.O. 5. Glenmark Pharmaceuticals S. A. 6. Glenmark Holding S.A. 7. Glenmark Pharmaceuticals S.R.L. 8. Glenmark Pharmaceuticals SP z.o.o. 9. Glenmark Pharmaceuticals Inc. (formerly Glenmark Generics Inc.) 10.Glenmark Therapeutics Inc. 11.Glenmark Farmaceutica Ltda 12.Glenmark Generics S.A 13.Glenmark Pharmaceuticals Mexico, S.A. DE C.V. 14.Glenmark Pharmaceuticals Peru SAC 15.Glenmark Pharmaceuticals Colombia SAS, Colombia (Formerly known as Glenmark Pharmaceuticals Colombia Ltda., Colombia) 16.Glenmark Uruguay S.A. 17.Glenmark Pharmaceuticals Venezuela, C.A 18.Glenmark Dominicana SRL 19.Glenmark Pharmaceuticals Egypt S.A.E. 20.Glenmark Pharmaceuticals FZE 21.Glenmark Impex L.L.C 22.Glenmark Philippines Inc. 23. Glenmark Pharmaceuticals (Nigeria) Ltd. 24. Glenmark Pharmaceuticals Malaysia Sdn Bhd 25. Glenmark Pharmaceuticals (Australia) Pty Ltd 26. Glenmark South Africa (pty) Ltd 27. Glenmark Pharmaceuticals South Africa (pty) Ltd 28. Glenmark Pharmaceuticals (Thailand) Co. Ltd 29. Glenmark Pharmaceuticals B.V. (Formerly known as Glenmark Generics B.V.) 30. Glenmark Arzneimittel Gmbh 31.Glenmark Pharmaceuticals Canada Inc. (formerly Glenmark Generics Canada Inc.) 32.Glenmark Pharmaceuticals Kenya Ltd 33.Glenmark Therapeutics AG 34. Viso Farmaceutica S.L., Spain 35. Glenmark Specialty SA 36. Glenmark Pharmaceuticals Distribution s.r.o. 37. Glenmark Pharmaceuticals Nordic AB 38. Glenmark Ukraine LLC 39. Glenmark-Pharmaceuticals Ecuador S.A. 40. Glenmark Pharmaceuticals Singapore Pte. Ltd.

For and on behalf of the Board of Directors

Glenn Saldanha Chairman & Managing Director

Mumbai, August 10, 2018